文献速递神经创伤神经重症

快速游离DNA检测预测脑震荡后综合征:单中心前瞻性预试验

Quick cell-free DNA testing for the prediction of postconcussion syndrome: a single-center prospective pilot trial.
PubMed 文献 · J Neurosurg · 2021-10-08

该单中心前瞻性预试验纳入30例轻度创伤性脑损伤(mTBI)患者,入院时用快速SYBR Gold法测循环游离DNA(cfDNA),3-4个月后18例完成认知评估。mTBI组cfDNA中位数高于匹配健康对照(730.5 vs 521.5 ng/ml,p=0.0395),入院cfDNA与CTT1、CTT2评分负相关(r=-0.559、-0.599)。作者认为cfDNA有望用于急诊筛查脑震荡后综合征(PCS),需大规模研究验证。

要点

  • mTBI患者入院cfDNA中位数730.5 ng/ml,高于匹配健康对照521.5 ng/ml(p=0.0395)。
  • 入院cfDNA与CTT1、CTT2评分负相关(r=-0.559、-0.599),水平越高认知表现越差。
  • cfDNA>800 ng/ml组CTT评分低于正常cfDNA组(p<0.001),提示可筛查PCS高危者。

核心结论

  • 快速检测的cfDNA有潜力作为急诊筛查PCS的生物标志物,但需大规模研究确立其早期预测价值。

研究设计与样本

  • 单中心前瞻性预试验,招募30例mTBI患者,入院时问卷并采血测cfDNA,3-4个月后18例返回完成认知评估与CTT。
  • 采用快速SYBR Gold法测量cfDNA,并与匹配健康对照比较。

主要发现

  • mTBI组cfDNA中位数高于匹配健康对照(730.5 vs 521.5 ng/ml,p=0.0395)。
  • 入院cfDNA浓度与CTT1和CTT2标准化测试表现负相关(r=-0.559和-0.599)。
  • cfDNA正常mTBI患者表现与健康参与者相似,cfDNA升高(>800 ng/ml)组CTT评分低于正常cfDNA组(p<0.001)。
  • CTT1提示中/重度认知损害者cfDNA中位数高于轻度或正常者(1186 vs 473.5 ng/ml,p=0.0441,AUC=0.8393)。
  • 18例返回评估者中三分之一报告工作时长减少,4例(22.2%)改变驾驶模式,5例(27.7%)减少或停止体育活动。

临床怎么用

  • 急诊可考虑用快速cfDNA检测辅助识别mTBI后PCS高危患者,以加强随访与认知评估。
  • cfDNA升高(>800 ng/ml)者CTT评分更低,提示需更密切的神经认知随访。

局限性

  • 为单中心预试验,样本量小(30例招募、18例完成认知评估),结论需大规模研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Mild traumatic brain injury (mTBI) is a major cause of emergency room (ER) admission. Thirty percent of mTBI patients have postconcussion syndrome (PCS), and 15% have symptoms for over a year. This population is underdiagnosed and does not receive appropriate care. The authors proposed a fast and inexpensive fluorometric measurement of circulating cell-free DNA (cfDNA) as a biomarker for PCS. cfDNA is a proven, useful marker of a variety of acute pathological conditions such as trauma and acute illness. METHODS: Thirty mTBI patients were recruited for this prospective single-center trial. At admission, patients completed questionnaires and blood was drawn to obtain cfDNA. At 3-4 months after injury, 18 patients returned for cognitive assessments with questionnaires and the Color Trails Test (CTT). The fast SYBR Gold assay was used to measure cfDNA. RESULTS: Seventeen men and 13 women participated in this trial. The mean ± SD age was 50.9 ± 13.9 years. Of the 18 patients who returned for cognitive assessment, one-third reported working fewer hours, 4 (22.2%) changed their driving patterns, and 5 (27.7%) reduced or stopped performing physical activity. The median cfDNA level of the mTBI group was greater than that of the matched healthy control group (730.5 vs 521.5 ng/ml, p = 0.0395). Admission cfDNA concentration was negatively correlated with performance on the CTT1 and CTT2 standardized tests (r = -0.559 and -0.599), meaning that greater cfDNA level was correlated with decreased cognitive performance status. The performance of the patients with normal cfDNA level included in the mTBI group was similar to that of the healthy participants. In contrast, the increased cfDNA group (> 800 ng/ml) had lower scores on the CTT tests than the normal cfDNA group (p < 0.001). Furthermore, patients with moderate/severe cognitive impairment according to CTT1 results had a greater median cfDNA level than the patients with scores indicating mild impairment or normal function (1186 vs 473.5 ng/ml, p = 0.0441, area under the receiver operating characteristic curve = 0.8393). CONCLUSIONS: The data from this pilot study show the potential to use cfDNA, as measured with a fast test, as a biomarker to screen for PCS in the ER. A large-scale study is required to establish the value of cfDNA as an early predictor of PCS.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Ben Zvi I, Harel OS, Douvdevani A, et al. Quick cell-free DNA testing for the prediction of postconcussion syndrome: a single-center prospective pilot trial. J Neurosurg. 2021. PMID: 34624860. doi:10.3171/2021.5.JNS21501

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。